N Stuart
Bangor University
4 Papers
N Stuart is an academic researcher from Bangor University. The author has contributed to research in topics: Exemestane & Tamoxifen. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.
R. C. Coombes,Emma Hall,Lorna Gibson,Robert Paridaens,Jacek Jassem,Thierry Delozier,Stephen E. Jones,Isabel Alvarez,Gianfilippo Bertelli,Olaf Ortmann,Alan S. Coates,Emilio Bajetta,D. Dodwell,Robert E. Coleman,Lesley Fallowfield,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,Alan L Stewart,N Stuart,Claire Snowdon,M. Carpentieri,Giorgio Massimini,Judith M Bliss +24 more
TL;DR: Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment.
Clinicians' attitudes towards clinical trials of cancer therapy
Elizabeth Ford,Valerie Jenkins,Lesley Fallowfield,N Stuart,Daniel Farewell,Vernon T. Farewell +5 more
TL;DR: Clinicians belonging to breast and colorectal teams were less disappointed about not enrolling patients in trials and more accepting of no-treatment arm trials, and research orientation was higher in physicians than surgeons and higher in specialist centres than district hospitals.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Janet E. Brown,Kara-Louise Royle,Walter M Gregory,Christy Ralph,Anthony Maraveyas,O.S. Din,Tim Eisen,Paul Nathan,Thomas Powles,Richard Griffiths,Robert Jones,Naveen S. Vasudev,Matthew Wheater,A. Hamid,T. Waddell,Rhona McMenemin,Poulam M. Patel,James Larkin,Guy Faust,Jayne Swain,Janine C Bestall,Christopher McCabe,David M. Meads,Vicky Goh,Tze Min Wah,Julia Brown,Jenny Hewison,Peter Selby,Fiona Collinson,Judith E. Carser,Gopalakrishnan Srinivasan,Fiona Thistlewaite,Ashraf Azzabi,Mark Beresford,David Farrugia,Marios P. Decatris,Carys Thomas,Joanna Gale,J. J. McAleer,A. Clayton,Ekaterini Boleti,T. Geldart,Santhanam Sundar,Jason F. Lester,Nachi Palaniappan,Mohan Hingorani,Khaliqur Rehman,Mohammad Emrul Hasan Khan,Naveed Sarwar,Janine Graham,Alastair M. Thomson,Narayanan Srihari,D. Sheehan,Rajaguru Srinivasan,O. Khan,Andrew Stockdale Jane Worlding,Stergios Boussios,N Stuart,Carey F MacDonald-Smith,F. Danwata,Duncan McLaren,Aravindhan Sundaramurthy,Anna Lydon,Sharon Beesley,Kathryn Lees,Mohini Varughese,Emma Gray,Angela Scott,Mark Baxter,Anna Mullard,Pasquale F. Innominato,Gaurav Kapur,Ashok Kumar,Natalie Charnley,C. Manetta,Prabir Chakraborti,Prantik Das,Sarah Rudman,H. Taylor,Christos Mikropoulos,Martin Highley,D Muthukumar,Anjali Zarkar,Roy Vergis,Seshadri Sriprasad,P. Brulinski,Amanda Clarke,R.D. Osbourne,Melanie Harvey,Renata Dega,G. Sparrow,Urmila Barthakur,E. Beaumont,Agnieszka Michael,Emilio Porfiri,Faisal Azam,Ravi Kodavtiganti +96 more
TL;DR: In this article , the authors compared a drug-free interval strategy with a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma (CRC) patients.
37
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes,Lucy Kilburn,Claire Snowdon,Robert Paridaens,Robert E. Coleman,Stephen E. Jones,Jacek Jassem,Cjh van de Velde,Thierry Delozier,Isabel Alvarez,L. Del Mastro,Olaf Ortmann,K Diedrich,Alan S. Coates,Emilio Bajetta,Stig Holmberg,D. Dodwell,Elizabeth Mickiewicz,Jens O. Andersen,Per Eystein Lønning,G. Cocconi,John F. Forbes,Monica Castiglione,N Stuart,Alan L Stewart,Lesley Fallowfield,Gianfilippo Bertelli,Emma Hall,R. G. Bogle,M. Carpentieri,E Colajori,M Subar,E. Ireland,Judith M Bliss +33 more
TL;DR: The results suggest that early improvements in disease-free survival noted in patients who switch to exemestane after 2-3 years on tamoxifen persist after treatment, and translate into a modest improvement in overall survival.